A brand new listing today – Emcure Pharma. As against the IPO price of Rs.1008, it got listed at Rs.1325, a premium of 31%. It went up to Rs.1384 and is now trading at Rs.1356 levels.

The IPO did well, subscribing 67.87x, with QIBs portion at 195.83x, HNIs at 48.32x and Retail at 7.21x.

The company is the leader in Indian gynecology and HIV anti-viral therapeutic market, with 13.5% market share in gynecology.

In our IPO Analysis, we had concluded - Company faces growth challenge and drop in profits when peers are growing highlights stress in business. Hence, we do not recommend applying in the IPO.